The effect of methimazole on Nethyl-N-hydroxyethylnitrosamine (EHEN)-induced renal lesions was investigated in a medium-term initiation/promotion bioassay in male Wistar rats. EHEN-initiated rats underwent unilateral nephrectomy of the left kidney and subsequent addition of the renal tumor promoters trisodium nitrilotriacetate (NTA), potassium dibasic phosphate (PDP), or hydroquinone (HQ), alone or in combination with methimazole, to the diet for 20 wk. The addition of methimazole reduced the severity of simple and adenomatous renal hyperplasias induced by NTA, PDP, and HQ, but had no effect on the number of renal cell tumors that arose in EHEN + NTA groups. Methimazole also decreased the bromodeoxyuridine (BrdU) labeling indices, but had little effect on the expression of &alpha; 2u -globulin in treated kidneys as compared to controls. It appears that methimazole exhibits antagonistic properties to nongenotoxic nephrotoxins, protecting against renal damage but not against tumorigenesis, probably arising from genotoxic insult.
INTRODUCTION
The damage induced in the rodent kidney by a number of nongenotoxic nephrotoxins has been shown to play an important role in the pathogenesis of renal tumors. The amount of damage, however, depends upon the magnitude of the individual dose, the duration and frequency of administration, and the route of exposure (8) . Although the underlying mechanisms in renal tumorigenesis may differ for genotoxic and nongenotoxic kidney toxins, there appears to be a basic cascade of effects induced by toxic insult involving cellular degeneration and death, with resultant regeneration and, potentially, hyperplasia. In the proximal tubules of the male rat, the accumulation of conjugated a2u-globulin and hydrocarbons from unleaded gasoline exposure causes cytotoxicity and cell death, resulting in increased cell proliferation and hyperplasia (1, 2) . A similar mechanism is hypothesized for the promotional effects exhibited by other nongenotoxic nephrotoxins, and, in some cases, it appears that prevention of the initial nephropathy can arrest the promotional pro-cess. Potassium citrate has recently been shown to inhibit the formation of renal tumors in N-ethyl-Nhydroxyethylnitrosamine (EHEN)-initiated rats promoted with potassium dibasic phosphate (PDP), an agent that normally produces severe nephropathy via precipitation and deposition of calcium phosphate (4, 9) .
Methimazole, a thionamide with antioxidant properties, was recently reported to protect the rat kidney from cephaloridine-induced damage (13) . Cephaloridine is a cephalosporin known to cause lipid peroxidation-type injury to the membranes in the proximal tubules. Using a medium-term renal carcinogenicity bioassay, we sought to investigate the effect of methimazole on the promotional capabilities of various types of nephrotoxic and potentially carcinogenic agents.
MATERIALS AND METHODS
Chemical. EHEN [CAS: [3] 47-25-6, 2-(ethylnitrosamine) ethanol, purity 99.8%, liquid at room temperature] was purchased from Nacalai Chemicals Ltd. (Kyoto, Japan) and mixed at a concentration of 1,000 ppm in basal meal diet (Oriental M powder, Oriental Yeast Co., Osaka, Japan). Trisodium nitrilotriacetate (NTA), hydroquinone (HQ), potassium dibasic phosphate (PDP), and methi- Abbreviations: BD = basal diet; BW = body weight; EHEN = N-ethyl-N-hydroxyethylnitrosamine; HQ = hydroquinone; KW = kidney weight; Met = methimazole; NTA = trisodium nitrilotriacetate; PDP = potassium dibasic phosphate.° Significantly different from group 10 (p < 0.05). b Significantly different from group 8 (p < 0.05). mazole (2-mercapto-1-methylimidazole) (Nacalai Chemicals Ltd., Kyoto, Japan) were mixed in basal diet at concentrations of 1 %, 2%, 10%, and 300 ppm, respectively.
Animals and Experimental Design. A total of 200 male Wistar rats (Std: Wistar) were purchased at 6 wk of age from Nihon SLC (Shizuoka, Japan) and acclimated on basal diet and tap water supplied ad libitum for 1 wk. All rats were housed in plastic cages at 24 ± 1 °C and 55 ± 5% relative humidity. At 7 wk of age, the animals were divided into 10 groups; groups 1-8 received 1,000 ppm EHEN in diet whereas groups 9 and 10 were given basal diet only. At experimental week 3 (10 wk of age), all rats underwent a unilateral nephrectomy of the left kidney and were subsequently taken off EHEN and placed on diets containing the test chemicals as follows : groups I and 4, 1 % NTA; groups 2 and 5, 10% PDP; groups 3 and 6, 2% HQ; groups 7 and 9, 300 ppm methimazole. Groups 1, 2, and 3 also received 300 ppm methimazole concomitantly with NTA, PDP, and HQ, respectively. Chemicals were administered for 18 wk.
Pathology. At termination of the assay at experimental week 20, urine and blood samples were taken from 5 randomly selected rats from each group for biochemistry. An additional 5 representative animals from each group were given a single ip injection of 100 mg/kg body weight of bromodeoxyuridine (BrdU; Sigma Chemical Co., St. Louis, MO, USA) I hr prior to sacrifice.
Individual whole body and kidney weights were recorded at necropsy. The kidneys and samples of small intestine from BrdU-treated rats were fixed in 70% ethanol for 24 hr and processed using the avidin-biotin peroxidase complex (ABC) technique for immunohistochemical studies of cell proliferation and DNA synthesis (9) . Tissues from the remaining animals were preserved in 10% neutral buffered formalin. After processing and embedding in paraffin, tissues were sectioned at 5 ~m and formalin-fixed tissues were stained with hematoxylin and eosin (H&E) for light microscopic histological evaluation. Additional sections were treated with monoclonal antibodies against a2,,-globulin, using a previously reported method (9) for immunohistochemical verification of protein expression.
Kidney lesions were classified as simple hyperplasia, adenomatous hyperplasia and renal cell tumor. This latter term includes both adenomas and carcinomas (4, 8, 9) . The numbers of each lesion type were averaged from counts taken in 4 sagittal sections of kidney per rat. Quantitative data were analyzed for statistical significance via the Student's t-test.
RESULTS
The mean body and kidney weights as well as average kidney-to-body weight ratios for each treatment group at 20 experimental weeks are summarized in Table I . The average body weights of animals in groups 1-4 and groups 6 and 7 were significantly lower than those of group 8 (EHEN alone). The mean for group 5 (EHEN + PDP), although low relative to group 8, was not significantly reduced. Significant decreases in the kidney-to-body weight ratios relative to group 8 were also revealed for groups 1 and 7; however, a statistically relevant increase in the ratio occurred only in groups 5 and 6.
Serum biochemistry demonstrated calcium levels significantly above the untreated control (group 10) for groups 1 and 2 and significantly lower for group 5, as shown in Table II . Phosphate levels were decreased significantly in groups 1, 4, 6, and 8, although the absolute values were not extremely different from the control (group 10) value. Urine creatinine and blood urea nitrogen showed no discernible variations related to treatment (data not shown). absence of pigmentation and degree of mineralization. As can be seen from Table III , treatment with EHEN and any of the promoting agents significantly increased the BrdU LI over that of both the untreated control (group 10) and animals fed methimazole only (group 9). Feeding methimazole concurrent with promoters reduced the LI over that of the matched promoter-only cohort in all cases, although the decrease was significant only between group 2 (EHEN/PDP + methimazole) and 5 (EHEN/ PDP). The addition of methimazole also appeared to have reduced the severity of nephropathy, in most cases to control levels, again in all but groups 2 and 5. Mineralization was observed in the cytoplasm of both proximal and distal tubular epithelium, in mesenchymal tissues, and in renal cell tumors from animals receiving PDP ± methimazole (Fig. 1 ). Kidneys from rats receiving HQ (±methimazol) showed a brown pigmentation in the cytoplasm of the proximal convoluted tubules (Fig. 2 ). sion of «2&dquo;-globulin throughout the treated groups was unchanged to insignificantly reduced as compared to expression in the untreated controls (data not shown).
By immunohistochemical evaluation, the expres-
The incidences of the various categories of renal lesions are compared in Table IV . Simple hyperplasias were significantly increased over control levels in all treatment groups with a single exception; animals receiving methimazole alone (group 9) showed a marked decrease in the incidence of simple hyperplasia over both EHEN and untreated control groups (groups 8 and 10, respectively). Adenomatous hyperplasias were not detected with feeding of methimazole only. The addition of methimazole to the promoter-laced feeds also significantly reduced the incidence of both simple and adenomatous hyperplasia over that of the promoter only-matched groups. Methimazole, however, seemed to have no effect on the incidence of renal cell tumors, which were confined only to groups receiving NTA (groups 1 and 4). H&E.
x 200.
DISCUSSION
Nephrotoxic agents are important factors in the process of renal carcinogenesis. Some may exert their effects directly on the cells of the kidney, whereas many others are metabolized to reactive intermediates involved in cytotoxicity and implicated in subsequent tumor formation. Increased cell proliferation is a result of cell degeneration and death, which are the common sequelae of toxic insult (8), whether it is caused by nephrotoxins, renal carcinogens, or by renal tumor promoters.
In previous studies, NTA and PDP have been shown to be renal tumor promoters in EHEN-initiated rats (3, 4) . Another renal tumor promoter, HQ, has been reported to enhance the development of nephropathies, notably tubular hyperplasias and adenomas, in male rats in chronic 2-yr bioassays (6, 13) . These chemicals appear to have different characteristics ; NTA is a weak carcinogen in its own right when given at high doses over long periods of time (8) . PDP and HQ appear to have no carcino-genic abilities in rats, but both induce chronic nephropathies, unrelated to £x2u-globulin expression, via different mechanisms. However, chronic nephropathy has the potential to increase the probability of expression of endogenously and exogenously induced mutations, eventually leading to tumorigenesis. Thus, given enough time, the renal promoters PDP and HQ may be renal carcinogens, as well.
The thionamide, methimazole, is known to interfere with synthesis of thyroid hormones by inhibiting the organification of iodine (15) . It has demonstrated the ability to protect against nephrotoxicity induced by such various agents as cephaloridine, S-( 1, 2-dichlorovinyl)-L-lysine, 2-bromohydroquinone, and cisplatin (12, 16) . The mechanism is likely to involve the antioxidant properties of methimazole and/or the related maintenance of protein thiol status in the kidney. Although the evidence for such is somewhat circumstantial, the fact that methimazole concentrates in renal tissue more than would be predicted by renal blood flow makes it an attractive agent for reducing renal oxidative damage (14) .
In this 20-wk bioassay, feeding NTA, PDP, and HQ increased the incidences of simple and adenomatous hyperplasias over the levels seen in controls. In addition, NTA promoted the formation of a small number of renal cell tumors. The simultaneous addition of methimazole to diets containing the promoters reduced hyperplasia, but had no effect on tumor formation in the NTA groups. This may not be totally unexpected.
HQ undergoes autoxidation to form quinone metabolites in aqueous solution in the presence of oxygen in vivo. It has been suggested that HQ nephrotoxicity is attributable to selective renal uptake of toxic glutathione conjugates mediated by y-glutamyltranspeptidase and followed by oxidation to the quinone (5, 11) . Oxygen radicals could react directly with DNA or RNA, or deplete the thiol groups of enzymes to allow cytotoxicity (13), a process that is interrupted by methimazole. In the present study, in fact, the most pronounced inhibition of renal hyperplasia by methimazole occurred in HQ-treated groups.
On the other hand, the nephropathies induced by PDP are probably due, at least in part, to calcium phosphate deposition in the kidney (9) . Intracellular calcium homeostasis is commonly disrupted in chemical toxicity; cell injury mediated by oxidative stress and pertubations of the plasma membrane releases sequestered calcium stores, resulting in intracellular calcium accumulation, renal acidosis, and coagulative necrosis. It is postulated that methimazole is able to block the distruption of calcium homeostasis and resultant intracellular calcium accretion.
Although methimazole was not able to protect against NTA-promoted renal cell tumors, it was able to reduce the BrdU LI and the incidence of both simple and adenomatous hyperplasia in treated kidneys. As was previously mentioned, NTA is, in itself, a weak renal carcinogen, possibly genotoxic in nature. It did not cause a high grade of nephropathy, but it appears to have been responsible for the greatest incidence of adenomatous hyperplasia in the study, with and without the concomitant administration of methimazole. There may be an additive carcinogenic effect between EHEN and NTA against which methimazole cannot protect, or methimazole may be useless against cell proliferation induced by mutations in oncogenes and/or tumor suppressor genes.
From the data generated, it seems clear that methimazole has an inhibitory effect on renal injury and regenerative hyperplasia in the rat, particularly when nephrotoxicity is related to oxidative injury. However, further studies are needed to elucidate the true protective mechanisms through which methimazole suppresses nephrotoxicty, and which may, it turn, reveal much more of the mechanisms of tumorigenesis as well.
